In prostate cancer, APC loss is also linked to homozygous deletion and truncation mutations in up to 7% of primary and 10.6% of metastatic cases (Table 1), resulting in the accumulation of β-catenin and elevated Wnt signaling. The gene discussed is APC; the disease is prostate carcinoma.